Effects of withdrawal of xuezhikang, an extract of cholestin, on lipid profile and C-reactive protein: A short-term time course study in patients with coronary artery disease

Cardiovascular Drugs and Therapy

Volumn 20, Issue 3, 2006, Pages 185-191

  Hu, Cheng Lin ^a   Li, Yan Bo ^a   Tang, Yan Hong ^a   Chen, Jiang Bing ^a   Liu, Jun ^a   Tang, Qi Zhu ^a   Zhang, Qing Hua ^a   Huang, Cong Xing ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

C reactive protein; Coronary artery disease; Lipids; Withdrawal; Xuezhikang

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; C REACTIVE PROTEIN; CHINESE DRUG; CHOLESTIN; FOSINOPRIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METOPROLOL; NITRATE; PLACEBO; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; XUEZHIKANG;

ADULT; ARTICLE; CARDIAC PATIENT; CHINESE MEDICINE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DIET RESTRICTION; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; HUMAN; LIPID ANALYSIS; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REBOUND; SHORT COURSE THERAPY; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL;

ANTICHOLESTEREMIC AGENTS; C-REACTIVE PROTEIN; CHOLESTEROL, LDL; CORONARY DISEASE; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; LIPIDS; MALE; MIDDLE AGED; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 33746218048     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-006-7947-x     Document Type: Article

References (28)

1. Pedersen TR, Kjekshus J, Berg K, Haghfelt T, Faergeman O, Faergeman G, Pyorala K, Miettinen T, Wilhelmsen L, Olsson AG, Wedel H. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. Atheroscler Suppl 2004;5:81-7.
2. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
3. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-9.
4. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998;279:1643-50.
5. Lee KT, Lai WT, Chu CS, Tsai LY, Yen HW, Voon WC, Sheu SH. Effect of withdrawal of statin on C-reactive protein. Cardiology 2004;102:166-70.
6. Retterstol L, Eikvar L, Bohn M, Bakken A, Erikssen J, Berg K. C-reactive protein predicts death in patients with previous premature myocardial infarction - a 10 year follow-up study. Atherosclerosis 2002;160:433-40.
7. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM Jr. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959-65.
8. Lai WT, Lee KT, Chu CS, Voon WC, Yen HW, Tsai LY, Sheu SH. Influence of withdrawal of statin treatment on proinflammatory response and fibrinolytic activity in humans: an effect independent on cholesterol elevation. Int J Cardiol 2005;98:459-64.
9. Spencer FA, Allegrone J, Goldberg RJ, Gore JM, Fox KA, Granger CB, Mehta RH, Brieger D. Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study. Ann Intern Med 2004;140:857-66.
10. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004;109(Suppl 1):III39-43.
11. Zhao SP, Liu L, Cheng YC, Shishehbor MH, Liu MH, Peng DQ, Li YL. Xuezhikang, an extract of cholestin, protects endothelial function through anti-inflammatory and lipid-lowering mechanisms in patients with coronary heart disease. Circulation 2004;110:915-20.
12. Jian J, Hao X, Deng C, Zhou H, Lin J. [The effects of xuezhikang on serum lipid profile, thromboxane A2 and prostacyclin in patients with hyperlipidemia]. Zhonghua Nei Ke Za Zhi 1999;38:517-9.
13. Heber D, Yip I, Ashley JM, Elashoff DA, Elashoff RM, Go VL. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr 1999;69:231-6.
14. Zhao SP, Liu L, Cheng YC, Li YL. Effect of xuezhikang, a cholestin extract, on reflecting postprandial triglyceridemia after a high-fat meal in patients with coronary heart disease. Atherosclerosis 2003;168:375-80.
15. Liu L, Zhao SP, Cheng YC, Li YL. Xuezhikang decreases serum lipoprotein(a) and C-reactive protein concentrations in patients with coronary heart disease. Clin Chem 2003;49:1347-52.
16. Li JJ, Hu SS, Fang CH, Hui RT, Miao LF, Yang YJ, Gao RL. Effects of xuezhikang, an extract of cholestin, on lipid profile and C-reactive protein: a short-term time course study in patients with stable angina. Clin Chim Acta 2005;352:217-24.
17. Lu ZL. [China coronary secondary prevention study (CCSPS)]. Zhonghua Xin Xue Guan Bing Za Zhi 2005;33:109-15.
18. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, Flaker GC, Braunwald E. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998;98:839-44.
19. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med 2000;343:1139-47.
20. Heeschen C, Hamm CW, Laufs U, Snapinn S, Bohm M, White HD. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002;105:1446-52.
21. Laufs U, Endres M, Custodis F, Gertz K, Nickenig G, Liao JK, Bohm M. Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. Circulation 2000;102:3104-10.
22. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002;106:1439-41.
23. Verma S, Li SH, Badiwala MV, Weisel RD, Fedak PW, Li RK, Dhillon B, Mickle DA. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002;105:1890-6.
24. Fichtlscherer S, Rosenberger G, Walter DH, Breuer S, Dimmeler S, Zeiher AM. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000;102:1000-6.
25. McGowan MP. There is no evidence for an increase in acute coronary syndromes after short-term abrupt discontinuation of statins in stable cardiac patients. Circulation 2004;110:2333-5.
26. Li JJ, Jiang H, Huang CX, Fang CH, Tang QZ, Xia H, Liu J, Li GS. Elevated level of plasma C-reactive protein in patients with unstable angina: its relations with coronary stenosis and lipid profile. Angiology 2002;53:265-72.
27. Speidl WS, Graf S, Hornykewycz S, Nikfardjam M, Niessner A, Zorn G, Wojta J, Huber K. High-sensitivity C-reactive protein in the prediction of coronary events in patients with premature coronary artery disease. Am Heart J 2002;144:449-55.
28. Abdelmouttaleb I, Danchin N, Ilardo C, Aimone-Gastin I, Angioi M, Lozniewski A, Loubinoux J, Le Faou A, Gueant JL. C-Reactive protein and coronary artery disease: additional evidence of the implication of an inflammatory process in acute coronary syndromes. Am Heart J 1999;137:346-51.